The international study, involving 24 medical centers in the United States and Europe, will be presented at the American Society of Clinical Oncology (http://www.asco.org/) annual meeting June 4-8, 2010, in Chicago.
Forty-five percent of patients with transformed lymphoma treated with lenalidomide responded positively to this immunomodulatory medication, which kills lymphoma cells by activating the body's natural killer cells and by interrupting cancer cell signaling that leads to cell death. Of those patients, 21 percent showed complete remission, some for more than a year.
Transformed lymphoma is an aggressive form of blood cancer. With current therapies, patients have a median survival rate of 1.7 years. In comparison, patients with indolent or slow-growing lymphoma can live 10 to 20 years with the disease. However, over the course of a decade, about 30 percent of those with indolent lymphoma develop transformed lymphoma.
"The study results show a remarkable response rate for transformed lymphoma patients who have a very poor prognosis," says Craig Reeder, M.D. (http://www.mayoclinic.org/bio/10010343.html), Mayo Clinic hematologist (http://www.mayoclinic.org/hematology-oncology-sct/) and principal investigator for the phase II study at Mayo Clinic's Arizona (http://www.mayoclinic.org/arizona/) campus. Phase II studies typically include no more than 300 patients and are designed to evaluate the effectiveness of a specific therapy.
The study included 217 patients with aggressive lymphoma. Of those, 33 had transformed lymphoma and were treated with lenalidomide. These patients ranged in age from 42 to 84. More than half had stage IV disease, where the lymphoma has spread to multiple sites or organs. All patients had been treated with chemotherapy and some with stem cell transplant to curtail the cancer. The median number of previous treatments was four and ranged up to 12.
Patients took lenalidomide pills (25 mg) daily for 21 days. For seven days, no medication was given. The medication continued until signs of cancer progression. Overall, 45 percent of patients responded positively to the therapy, but results varied by the particular type of transformed lymphoma.
For transformed follicular lymphoma, the most common form of the illness, 13 of the 23 patients (57 percent) in this subgroup responded positively to lenalidomide. Ten patients with other types of transformed lymphoma did not respond. They included transformed chronic lymphocytic leukemia, small lymphocytic lymphoma and others.
Dr. Reeder notes that while the number of patients treated with lenalidomide was small, the results are promising because of the response rate, the length of the response, and the simplicity of treatment. In patients who responded, the positive effect of lenalidomide was seen for a median of nearly 13 months. Compared to chemotherapy drugs, lenalidomide is easy to administer and is well tolerated. "Its appeal is that it's not toxic to the patient," he says. Side effects were considered mild and included low white blood cell counts.
Lenalidomide is approved by the U.S. Food and Drug Administration to treat multiple myeloma and certain types of myelodysplastic syndrome. Mayo Clinic researchers and others have been studying its potential as a lymphoma treatment for about two years. Further studies are needed to confirm its role in treating patients with transformed lymphoma.
VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Craig Reeder, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/05/26/study-identifies-promising-treatment-for-aggressive-lymphoma/).
About Mayo Clinic
For more than 100 years, millions of people from all walks of life have found answers at Mayo Clinic. These patients tell us they leave Mayo Clinic with peace of mind knowing they received care from the world's leading experts. Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. At Mayo Clinic, a team of specialists is assembled to take the time to listen, understand and care for patients' health issues and concerns. These teams draw from more than 3,700 physicians and scientists and 50,100 allied staff that work at Mayo Clinic's campuses in Minnesota, Florida, and Arizona; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To best serve patients, Mayo Clinic works with many insurance companies, does not require a physician referral in most cases and is an in-network provider for millions of people. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your general health information.
Karl Oestreich | EurekAlert!
Drone vs. truck deliveries: Which create less carbon pollution?
31.05.2017 | University of Washington
New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology